2-year survival data from a randomized study of peginterferon alfa-2a (40KD) vs interferon alfa-2a in patients with chronic-phase chronic myelogenous leukemia.

被引：0
|
作者：
Lipton, JH
Khoroshko, ND
Golenkov, AK
Abdulkadyrov, KM
Nair, MK
Raghunadharao, D
Brummendorf, T
Bergstrom, B
机构：
[1] Princess Margaret Hosp, Allogene BMT Program, Toronto, ON M4X 1K9, Canada
[2] Hematol Res Ctr, Dept Leucosis, Chemotherapy & Pathol Erithron, Moscow, Russia
[3] Moscow Regional Res Clin Inst, Dept Hematol Immunol, Moscow, Russia
[4] Russian Sci Res Inst Hematol & Transfusiol, Dept Hematol, St Petersburg, Russia
[5] Reg Canc Ctr, Dept Med Oncol, Trivandrum 695011, Kerala, India
[6] Nizams Inst Med Sci, Dept Med Oncol, Hyderabad, Andhra Pradesh, India
[7] Univ Tubingen, Med Klin Poliklin, Dept Hematol Oncol Immunol & Rheumatol, Tubingen, Germany
[8] Hoffmann La Roche Inc, Nutley, NJ USA
来源：
BLOOD | 2003年 / 102卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3363
引用
收藏
页码：904A / 904A
页数：1
相关论文
共 50 条
  • [41] Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1 - Reply
    Jeffers, LJ
    Cassidy, W
    Howell, CD
    Hu, S
    Reddy, KR
    HEPATOLOGY, 2004, 40 (03) : 761 - 761
  • [42] COST-EFFECTIVENESS ANALYSIS OF PEGINTERFERON ALFA-2A (40KD) IN HBEAG-NEGATIVE CHRONIC HEPATITIS B IN POLAND
    Jakubczyk, M.
    Paweska, J.
    Niewada, M.
    Berak, H.
    Szkultecka-debek, M.
    Russel-Szymczyk, M.
    VALUE IN HEALTH, 2011, 14 (07) : A277 - A277
  • [43] COST-EFFECTIVENESS ANALYSIS OF PEGINTERFERON ALFA-2A (40KD) IN HBEAG-POSITIVE CHRONIC HEPATITIS B IN POLAND
    Jakubczyk, M.
    Paweska, J.
    Niewada, M.
    Berak, H.
    Szkultecka-Debek, M.
    Russel-Szymczyk, M.
    VALUE IN HEALTH, 2011, 14 (07) : A275 - A275
  • [44] A comparison of cost effectiveness of peginterferon alfa-2a (40KD) (pegasys) plus ribavirin (copegus) vs interferon alfa-2b plus ribavirin as first treatment of chronic hepatitis C (CHC)
    Sullivan, SD
    Green, J
    Patel, KK
    Crtaxi, A
    Alberti, A
    Giuliani, G
    De Carli, C
    JOURNAL OF HEPATOLOGY, 2003, 38 : 174 - 175
  • [45] A tool for selecting patients with a high probability of sustained virological response to peginterferon alfa-2a (40kD)/ribavirin
    Ferenci, Peter
    Aires, Rodrigo
    Ancuta, Ioan
    Arohnson, Andrew
    Cheinquer, Hugo
    Delic, Dragan
    Gschwantler, Michael
    Larrey, Dominique
    Tallarico, Ludovico
    Schmitz, Manuela
    Tatsch, Fernando
    Ouzan, Denis
    LIVER INTERNATIONAL, 2014, 34 (10) : 1550 - 1559
  • [46] A randomized, open-label, multicenter study evaluating the efficacy of peginterferon alfa-2a versus interferon alfa-2a, in combination with ribavirin, in naive and relapsed chronic hepatitis C patients
    Nevens, F.
    Van Vlierberghe, H.
    D'Heygere, F.
    Delwaide, J.
    Adler, M.
    Henrion, J.
    Lenaerts, A.
    Hendliszs, A.
    Michielsen, P.
    Bastens, B.
    Brenard, R.
    Laureys, A.
    ACTA GASTRO-ENTEROLOGICA BELGICA, 2010, 73 (02): : 223 - 228
  • [47] Prospective evaluation of peginterferon alfa-2a (40KD)/ribavirin in CHC, IFN/ribavirin nonresponders/relapsers
    Parise, E
    Meirelles, A
    Martinelli, A
    Lacet, C
    Correa, E
    Cotrim, H
    Settee, H
    Cheinquer, H
    Gallizi, J
    Fonseca, J
    Parana, R
    da Silva, R
    Spinelli, V
    Gomes, A
    Crespo, D
    Lima, L
    Pereira, L
    Tiexeira, R
    Amorim, W
    Tatsch, F
    JOURNAL OF HEPATOLOGY, 2003, 38 : 161 - 161
  • [48] Treatment of chronic hepatitis C (cHC) with peginterferon Alfa-2a (40KD) (PEG) and ribavirin (RBV) in patients older than 60 years
    Meyer, Ulrike
    Zehnter, Elmar
    Mauss, Stefan
    Boeker, Klaus
    Lutz, Thomas
    Racky, Stefan
    Schmidt, Wolfgang
    Ullrich, Rainer
    Sbrijer, Innessa
    Heyne, Renate
    Schober, Andreas
    John, Christine
    Hey, Karl-Heinz
    Bokemeyer, Bernd
    Kallinowski, Birgit
    Moeller, Bernd
    Pape, Stefan
    Alshuth, Ulrich
    Hueppe, Dietrich
    GASTROENTEROLOGY, 2007, 132 (04) : A790 - A791
  • [49] Histologic benefit of peginterferon alfa-2a (40kd) (Pegasys®) monotherapy in patients with advanced fibrosis or cirrhosis due to chronic hepatitis C.
    Everson, G
    Heathcote, J
    Pappas, SC
    Govindarajan, S
    Lentz, E
    Lopez-Talavera, JC
    HEPATOLOGY, 2004, 40 (04) : 316A - 316A
  • [50] PEG-IFN alfa-2a (40KD) (Pegasys) plus ribavirin (RBV) vs IFN alfa-2a (Roferon-A) in naive patients with chronic hepatitis C (CHC) and genotype 1.
    Cariti, G
    Andreoni, M
    Calleri, G
    Manca, A
    Rosina, F
    Sartori, M
    Tabone, M
    Grasso, A
    Picciotto, A
    Smedile, A
    Rizzetto, M
    HEPATOLOGY, 2002, 36 (04) : 595A - 595A
12345